04.24.26 -- U.S. Pharma Tariffs And MFN Become Law After April 2 Update

Although polymer bags are an excellent choice for cold chain use, not all polymer films perform the same way, even if their specifications rate them for use at low temperatures.

Clinical trials for central nervous system therapies face significant obstacles to approval, including subjective endpoints and complex patient selection. Consider a strategic approach for success.

Immunology trials often place a sustained burden on participants. However, integrating Home Trial Support (HTS) into a Phase 3 immunology trial can help improve the overall study experience.

Stay current with the latest FDA investigator filing updates. Learn when to transition to the new version and how to maintain compliance without unnecessary administrative re-work.

In this episode of Few and Far Between, Sinan Golhan, the CEO and founder of Geltech Labs, discusses a significant technological gap in biotech: the lack of specialized lab robotics for hydrogels.

Vendor selection often fails due to five common dysfunctions. Identifying and addressing them early improves alignment, trust, and trial performance—avoiding costly delays.

Operational burden often falls on unequipped clinical sites, which creates a system prioritizing scale over quality, minimal site support, delayed timelines, and ultimately compromised trial outcomes.

Slow oncology trial enrollment raises costs and delays progress. AI prescreening, patient-focused engagement, and early pharmacology studies help accelerate recruitment and optimize trial design.

Clinical medical writing for gene therapy regulatory documents is a demanding, detail-oriented task that diverges significantly from medical writing for more traditional therapies.